meta
|
Preg
- medecines during pregnancy KB
Search
Tenofovir (local routes)
Overall results
Study description
Excluded studies
Table
Graphic
auto
during pregnancy (anytime or not specified)
1st trimester
2nd trimester
3rd trimester
2nd and/or 3rd trimester
throughout pregnancy
early pregnancy
days before delivery
late pregnancy
preconception-only
periconceptional
preconceptional for kinetic reason
at least 1st trimester
3 months (or more) before pregnancy or during pregnancy
1st and 2nd trimester
3 months or more before pregnancy or1st trimester
Whatever the period exposition
individual studies
Outcome
TE
95% CI
n cases
n exposed
k
Pub. bias
Growth parameters and prematurity
Preterm (< 37 weeks)
Sibeko (vaginal gel), 2011
1
0.44
[
0.04
; 4.71]
4
16
not evaluable
Maternal consequences
Caesarean
0
-
-
-
-
-
Postpartum hemorrhage
0
-
-
-
-
-
Neonatal disorders
Fetal distress
0
-
-
-
-
-
Neonatal death (< 28 days of life)
Sibeko (vaginal gel), 2011
1
0.18
[
0.01
; 3.75]
3
16
not evaluable
Intrauterine deaths
Early intrauterine death (< 22 weeks)
Sibeko (vaginal gel), 2011
1
0.54
[
0.12
; 2.38]
10
22
not evaluable
Elective/induced termination of pregnancy
Sibeko (vaginal gel), 2011
1
1.47
[
0.27
; 8.09]
6
22
not evaluable
Late intrauterine deaths (> 22 weeks)
Sibeko (vaginal gel), 2011
1
1.42
[
0.03
; 74.32]
-
22
not evaluable
0.0
100.0
1.0